Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Revenue (2016 - 2025)

United Therapeutics' Revenue history spans 17 years, with the latest figure at $790.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 10102.53% year-over-year to $790.2 million; the TTM value through Dec 2025 reached $3.2 billion, up 49.17%, while the annual FY2025 figure was $3.2 billion, 10.61% up from the prior year.
  • Revenue for Q4 2025 was $790.2 million at United Therapeutics, down from $799.5 million in the prior quarter.
  • Across five years, Revenue topped out at $799.5 million in Q3 2025 and bottomed at -$7.9 million in Q4 2024.
  • The 5-year median for Revenue is $511.4 million (2022), against an average of $532.6 million.
  • The largest annual shift saw Revenue tumbled 890.0% in 2024 before it skyrocketed 10102.53% in 2025.
  • A 5-year view of Revenue shows it stood at $415.2 million in 2021, then increased by 18.38% to $491.5 million in 2022, then crashed by 99.8% to $1.0 million in 2023, then crashed by 890.0% to -$7.9 million in 2024, then surged by 10102.53% to $790.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Revenue are $790.2 million (Q4 2025), $799.5 million (Q3 2025), and $798.6 million (Q2 2025).